Controlled release formulations for the delivery of HIF-1 inhibitors

• US 9,950,072 B2
• Filed: 01/19/2015
• Issued: 04/24/2018
• Est. Priority Date: 03/16/2012
• Status: Active Grant

• Current Assignee: Johns Hopkins University
• Original Assignee: Johns Hopkins University
• Inventors: Hanes, Justin Scot, Campochiaro, Peter Anthony, Fu, Jie
• Primary Examiner(s): McIntosh, III, Traviss C
• Application Number:
  US14/599,853
• Publication Number:
  US 20150141359A1
• Time in Patent Office: 1,191 Days
• Field of Search: None
• CPC Class Codes: A61K 31/704 attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin digitoxin A61K31/7048
• CPC Class Codes: A61K 47/50 the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
• CPC Class Codes: A61K 47/59 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
• CPC Class Codes: A61K 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• CPC Class Codes: A61K 47/6907 the form being a microemulsion, nanoemulsion or micelle
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61K 9/14 Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51
• CPC Class Codes: A61K 9/16 Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction A61K9/20 takes precedence if the final form is a tablet; microspheres with drug-free outer coating, microcapsules A61K9/50; mixture of different granules, microcapsules, (coated) microparticles A61K9/5084; nanoparticles A61K9/51
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/10 for accommodation disorders, e.g. myopia
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system

Abstract

Controlled release dosage formulations for the delivery of one or more HIF-1 inhibitors are provided. The controlled release formulations contain one or more HIF-1 inhibitors conjugated to or dispersed in a polymeric vehicle. The one or more HIF-1 inhibitors can be dispersed or encapsulated in a polymeric matrix. In some embodiments, the one or more HIF-1 inhibitors are covalently bound to a polymer, forming a polymer-drug conjugate. Polymeric vehicles can be formed into implants, microparticles, nanoparticles, or combinations thereof. Controlled release HIF-1 formulations provide prolonged therapeutic benefit while lowering side effects by releasing low levels of one or more HIF-1 inhibitors and/or HIF-1 inhibitor conjugates over a prolonged period of time. Controlled release dosage formulations can be used to treat or prevent a disease or disorder in a patient associated with vascularization, including cancer, obesity, and ocular diseases such as wet AMD.

Claims

1. Micro- and/or nanoparticles formed of polymeric conjugates defined by one of the following formulae

(A-X)_m—

Y—

((Z)_o—

(X)_p-(A)_q)_n

wherein

A represents, independently for each occurrence, a HIF-1 inhibitor;

X represents, independently for each occurrence, a hydrophobic polymer segment;

Y is absent, or represents a branch point;

Z represents, independently for each occurrence, a hydrophilic polymer segment; and

o is 1;

p and q are independently 0 or 1;

m is an integer between one and twenty; and

n is an integer between one and twenty.

2. The micro- and/or nanoparticles of claim 1, wherein A is an anthracycline.

3. The micro- and/or nanoparticles of claim 1, wherein Z is selected from the group consisting of a poly(alkylene glycol), a polysaccharide, poly(vinyl alcohol), polypyrrolidone, a polyoxyethylene block copolymer (PLURONIC®

), and copolymers thereof.

4. The micro- and/or nanoparticles of claim 3, wherein Z for each occurrence comprises polyethylene glycol.

5. The micro- and/or nanoparticles of claim 1, wherein X is biodegradable.

6. The micro- and/or nanoparticles of claim 5, wherein X is selected from the group consisting of polyesters, polycaprolactone, polyanhydrides, and copolymers thereof.

7. The micro- and/or nanoparticles of claim 6, wherein X comprises a polyanhydride.

8. The micro- and/or nanoparticles of claim 7, wherein X comprises polysebacic anhydride.

9. The micro- and/or nanoparticles of claim 7, wherein X comprises 1,6 bis(p-carboxyphenoxy)hexane (CPH) or a combination of poly-CPH (PCPH) and polysebacic anhydride.

10. The micro- and/or nanoparticles of claim 1, wherein Y is from one of the following:

11. The micro- and/or nanoparticles of claim 10, wherein Y is from citric acid.

12. The micro- and/or nanoparticles of claim 1, defined by the following formula

A-X—

YZ)_n

wherein

A represents, independently for each occurrence, a HIF-1 inhibitor;

X represents, a hydrophobic polymer segment;

Y represents a branch point;

Z represents, independently for each occurrence, a hydrophilic polymer segment; and

n is an integer between one and ten or two and ten.

13. The micro- and/or nanoparticles of claim 12, wherein A is an anthracycline.

14. The micro- and/or nanoparticles of claim 12, wherein Z is selected from the group consisting of a poly(alkylene glycol), a polysaccharide, poly(vinyl alcohol), polypyrrolidone, a polyoxyethylene block copolymer, and copolymers thereof.

15. The micro- and/or nanoparticles of claim 14, wherein Z for each occurrence comprises polyethylene glycol.

16. The micro- and/or nanoparticles of claim 12, wherein X is biodegradable.

17. The micro- and/or nanoparticles of claim 16, wherein X is selected from the group consisting of polyesters, polycaprolactone, polyanhydrides, and copolymers thereof.

18. The micro- and/or nanoparticles of claim 17, wherein X comprises a polyanhydride.

19. The micro- and/or nanoparticles of claim 18, wherein X comprises polysebacic anhydride.

20. The micro- and/or nanoparticles of claim 17, wherein X comprises 1,6 bis(p-carboxyphenoxy)hexane (CPH) or a combination of CPH and polysebacic anhydride.

21. The micro- and/or nanoparticles of claim 12, wherein n is between 2 and 6.

22. The micro- and/or nanoparticles of claim 21, wherein n is 3.

23. The micro- and/or nanoparticles of claim 12, wherein Y is from one of the following:

24. The micro- and/or nanoparticles of claim 23, wherein Y is from citric acid.

25. The micro- and/or nanoparticles of claim 1, wherein the polymeric conjugate is defined by Formula I

26. The micro- and/or nanoparticles of claim 25, wherein X is biodegradable.

27. The micro- and/or nanoparticles of claim 25, wherein X is selected from the group consisting of polyesters, polycaprolactone, polyanhydrides, and copolymers thereof.

28. The micro- and/or nanoparticles of claim 27, wherein X comprises a polyanhydride.

29. The micro- and/or nanoparticles of claim 28, wherein X comprises polysebacic anhydride.

30. The micro- and/or nanoparticles of claim 26, wherein X comprises 1,6 bis(p-carboxyphenoxy)hexane (CPH) or a combination of CPH and polysebacic anhydride.

31. The micro- and/or nanoparticles of claim 25, wherein one or more of L are amides or esters.

32. The micro- and/or nanoparticles of claim 31, wherein A is an anthracycline.

33. The micro- and/or nanoparticles of claim 1, wherein the polymeric conjugate is defined by Formula IA

34. The micro- and/or nanoparticles of claim 33, wherein A is an anthracycline.

35. The micro- and/or nanoparticles of claim 33, wherein X is biodegradable.

36. The micro- and/or nanoparticles of claim 35, wherein X comprises a polyanhydride.

37. The micro- and/or nanoparticles of claim 36, wherein X comprises polysebacic anhydride.

38. The micro- and/or nanoparticles of claim 36, wherein X comprises 1,6 bis(p-carboxyphenoxy)hexane (CPH) or a combination of CPH and polysebacic anhydride.

39. A formulation comprising the micro- and/or nanoparticles of claim 1 in a pharmaceutically acceptable carrier.

40. A formulation comprising the micro- and/or nanoparticles of claim 12.

41. A formulation comprising the micro- and/or nanoparticles of claim 25.

42. The formulation of claim 39, comprising a conjugate defined by the following formula

A-X

wherein

A is a HIF-1 inhibitor;

and

X is a hydrophobic polymer segment.

43. The formulation of claim 42, wherein A is an anthracycline.

44. The formulation of claim 42, wherein X comprises a polyanhydride.

45. The formulation of claim 44, wherein X comprises polysebacic anhydride.

46. The conjugate of claim 44, wherein X comprises 1,6 bis(p-carboxyphenoxy)hexane (CPH) or a combination of CPH and polysebacic anhydride.

47. A method of treating a disease or disorder involving aberrant vascularization, comprising administering to a patient in need thereof the formulation of claim 39, in a pharmaceutically acceptable excipient.

48. A method of treating an intraocular neovascular disease or disorder of the eye comprising administering to the eye of a patient in need thereof the formulation of claim 39, in an excipient, pharmaceutically acceptable for administration to the eye.

49. The method of claim 48, wherein the intraocular neovascular disease or disorder is selected from the group consisting of age-related macular degeneration associated with choroidal neovascularization, proliferative diabetic retinopathy, proliferative vitreoretinopathy, retinopathy of prematurity, pathological myopia, von Hippel-Lindau disease, presumed ocular histoplasmosis syndrome (POHS), branch retinal vein occlusion, central retinal vein occlusion, branch retinal artery occlusion, central retinal artery occlusion, neovascularization associated with a tumor, neovascularization associated with an ocular wound, retinal neovascularization, corneal graft rejection, complications from surgery that cause neovascularization, complications from injury that cause neovascularization, and combinations thereof.

50. The method of claim 49, wherein the disease or disorder is wet age-related macular degeneration.

51. The method of claim 49, wherein the disease or disorder involves choroidal neovascularization.

52. The method of claim 51, wherein the formulation provides an effective amount of one or more HIF-1 inhibitors to decrease the area of choroidal neovascularization, as measured by fluorescein angiography, by at least 15%.

53. The method of claim 49, wherein the disease or disorder involves retinal neovascularization.

54. The method of claim 53, wherein the formulation provides an effective amount of one or more HIF-1 inhibitors to decrease the area of retinal neovascularization, as measured by fluorescein angiography, by at least 15%.